Bolt Biotherapeutics, Inc. Common Stock BOLT
Key Stats
- Today's Range
- $4.65 – $4.97
- 50-Day Range
- $3.91 – $5.74
- 52-Week Range
- $3.91 – $9.25
- Volume
- 22K shs
- Average Volume
- 30K shs
- Market Cap
- $9.51 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.48
- Price / Sales
- 1.46
Short Interest
- Short Interest
- 22.68%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $6.50 million
- Net Income
- $-29,580,000
- Net Margin
- -455.15%
- Return on Equity
- -149.23%
- Debt-to-Equity
- —
About Bolt Biotherapeutics, Inc. Common Stock
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.